OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Want to see OKUR full AI Analyst Report?
Top Page
OnKure Therapeutics
(NASDAQ:OKUR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-20.00% Downside)
Action:Reiterated
Date:06/05/26
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and persistent cash burn). Technicals are neutral-to-slightly constructive, and recent financing supports runway, but valuation remains constrained by continued losses and lack of dividend support.
Positive Factors
Balance sheet strength
Very low leverage and materially improved equity/assets provide financial flexibility for a development-stage biotech. Sustained capitalization reduces immediate solvency risk, enabling multi-stage clinical programs to proceed without near-term debt pressure.
Negative Factors
Persistent cash burn
Ongoing, large negative free cash flow and widening net losses are structural for a pre-revenue biotech and drive recurring funding needs. Continued cash burn pressures strategic optionality and elevates dilution or financing risk if development timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and materially improved equity/assets provide financial flexibility for a development-stage biotech. Sustained capitalization reduces immediate solvency risk, enabling multi-stage clinical programs to proceed without near-term debt pressure.
Read all positive factors
OnKure Therapeutics (OKUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$169.66M
Dividend YieldN/A
Average Volume (3M)86.56K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth25.85%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.33
Shares Outstanding40,395,480
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit658.05
Enterprise Value/Ebitda2.31
Forecast
1Y Price Target
$23.00Price Target Upside360.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.79
Revenue Forecast (FY)$666.67K
OnKure Therapeutics Business Overview & Revenue Model
Company Description
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developi...
How the Company Makes Money
null...
OnKure Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -203.00K | -830.00K | 0.00 | 0.00 | 0.00 | -50.00K |
| EBITDA | -57.92M | -58.69M | -51.71M | -34.75M | -29.13M | -39.72M |
| Net Income | -58.75M | -59.52M | -52.67M | -35.31M | -29.51M | -39.77M |
Balance Sheet | ||||||
| Total Assets | 198.69M | 62.12M | 114.91M | 35.73M | 16.00M | 154.02M |
| Cash, Cash Equivalents and Short-Term Investments | 192.11M | 59.05M | 110.76M | 29.88M | 11.54M | 147.67M |
| Total Debt | 409.00K | 549.00K | 1.08M | 674.00K | 637.00K | 0.00 |
| Total Liabilities | 14.34M | 5.93M | 11.08M | 137.58M | 70.42M | 6.81M |
| Stockholders Equity | 184.35M | 56.18M | 103.83M | -101.84M | -54.42M | 147.21M |
Cash Flow | ||||||
| Free Cash Flow | -50.79M | -51.87M | -51.17M | -34.79M | -28.09M | -38.18M |
| Operating Cash Flow | -50.76M | -51.83M | -51.12M | -34.55M | -26.95M | -37.98M |
| Investing Cash Flow | -33.00K | -46.00K | 15.87M | -246.00K | -1.13M | -23.38M |
| Financing Cash Flow | 146.24M | 163.00K | 116.13M | 53.13M | 26.46M | 132.41M |
OnKure Therapeutics Technical Analysis
Positive
5.00
Price Trends
4.28
Negative
3.72
Positive
3.31
Positive
Market Momentum
0.05
Negative
52.11
Neutral
34.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKUR, the sentiment is Positive. The current price of 5 is above the 20-day moving average (MA) of 4.07, above the 50-day MA of 4.28, and above the 200-day MA of 3.31, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 52.11 is Neutral, neither overbought nor oversold. The STOCH value of 34.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OKUR.
OnKure Therapeutics Risk Analysis
OnKure Therapeutics disclosed 71 risk factors in its most recent earnings report. OnKure Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OnKure Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $169.66M | -0.98 | -61.02% | ― | ― | 25.85% | |
47 Neutral | $94.16M | -4.70 | -245.45% | ― | 164.08% | 58.49% | |
46 Neutral | $42.44M | 0.84 | -560.64% | ― | -32.64% | 56.66% | |
44 Neutral | $28.03M | -4.07 | -94.51% | ― | ― | ― |
* Healthcare Sector Average
OKUR
OnKure Therapeutics
4.20
1.78
73.55%
IGC
IGC Pharma
0.28
-0.02
-6.67%
ELUT
Elutia
0.97
-0.80
-45.31%
RANI
Rani Therapeutics Holdings
0.77
0.26
50.59%
OnKure Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan
Positive
Jun 4, 2026
On June 3, 2026, OnKure Therapeutics, Inc. stockholders approved an amended and restated 2024 Equity Incentive Plan that increases the share reserve by 3,231,638 shares, removes the fixed numerical cap in the annual “evergreen” provisi...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
OnKure Announces $150M Private Placement and Board Changes
Positive
Mar 30, 2026
On March 27, 2026, OnKure Therapeutics entered into a $150 million private placement with institutional investors to sell 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants for 9,430,959 additional shares, with cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.